Claims for Patent: 8,383,144

Summary for Patent: 8,383,144

Title:	Tissue adhering compositions
Abstract:	A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25% or less that, when mixed with the first component within a reaction pH range, cross-links with the first component to form a non-liquid, three-dimensional barrier. The buffer material includes tris-hydroxymethylaminomethane having a pH within the reaction pH range. The method applies the mixture to adhere to a tissue region.
Inventor(s):	Hnojewyj; Olexander (Saratoga, CA)
Assignee:	Neomend, Inc. (Irvine, CA)
Application Number:	12/641,215
Patent Claims:	1. A method comprising: mixing a first electrophilic polymer material comprising poly(ethylene glycol) having a functionality of greater than or equal to three and a second electrophilic polymer material comprising a linear polymer with a solution comprising recombinant serum albumin having a concentration of about 25% by weight or less and a buffer material comprising tris-hydroxymethylaminomethane, said buffer material being capable of providing a reaction pH range of between about 8 to about 10, and applying the mixture to a tissue region, wherein the first electrophilic polymer material and the second electrophilic polymer material crosslink with the recombinant serum albumin to form a mechanical barrier. 2. A method according to claim 1, wherein the first electrophilic polymer material has a molecular weight of 10,500.+-.1500. 3. A method according to claim 1, wherein the buffer material further comprises carbonate. 4. A method according to claim 3, wherein the solution comprising the recombinant serum albumin has a pH of between 8.3 and 8.5 prior to mixing with the first component. 5. The method of claim 1, wherein the first electrophilic polymer comprises poly(ethylene glycol) (PEG) having a molecular weight of between 9,000 and 12,000. 6. The method of claim 1, wherein the second electrophilic polymer comprises a linear polymer having a functionality of at least three. 7. The method of claim 1, wherein the first electrophilic polymer and the second electrophilic polymer each individually comprise a hydrolytically degradable moiety. 8. The method of claim 7, wherein the hydrolytically degradable moiety comprises saturated di-acids, unsaturated di-acids, poly(glycolic acid), poly(DL-lactic acid), poly(L-lactic acid), poly(.xi.-caprolactone), poly(.delta.-valerolactone), poly(.gamma.-butyrolactone), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(orthocarbonates), poly(phosphoesters), or derivatives thereof. 9. The method of claim 7, wherein the hydrolytically degradable moiety comprises glutarate, poly(DL-lactic acid), poly(L-lactic acid), or a combination thereof. 10. The method of claim 1, wherein the first electrophilic polymer and the second electrophilic polymer each individually comprise N-hydroxysuccinimide. 11. The method of claim 1, further comprising preparing a solution comprising of the first electrophilic polymer and the second electrophilic polymer. 12. The method of claim 11, wherein the solution comprises from 5 w/w % to 35 w/w % of the first electrophilic polymer and the second electrophilic polymer. 13. The method of claim 11, wherein the solution further comprises sterile water. 14. The method of claim 11, wherein the polymer solution comprises at least 50% by weight or more of the first electrophilic polymer.

Details for Patent 8,383,144

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2018-11-06